TipRanks
2 Strong buy stocks trade at steep discounts
Whether markets move up or down, every investor likes a bargain. There is an excitement in finding a valuable stock at a low, low price and seeing it appreciate in the medium to long term. The key here for investors is to find options in which the risk / reward combination will work to long-term benefit. So, how are investors supposed to distinguish between the names that are ready to get back on their feet and those that are going to stay in the landfill? This is what the benefits on Wall Street are for. Using TipRanks’ database, we have identified two selected stocks that analysts say are ready for a rebound. Despite the huge losses suffered over the past 52 weeks, the two ticks received enough praise from the street to achieve a consensus rating of ‘Strong Buy’. Theravance Biopharma (TBPH) We will start with Theravance, a biopharmaceutical company focusing on the development of organ-specific medicines. The current pipeline contains drug candidates for the treatment of inflammatory lung and intestinal conditions, as well as neurogenicortostatic hypotension. The research programs range from Phase 1 to Phase 3 trials. Theravance already has YUPELRI on the market as a COPD treatment. YUPELRI is the largest share of Theravance’s revenue, amounting to $ 18.3 million in the third quarter. It was 47% higher than a year-on-year and was driven by a 124% increase in YUPELRI sales. Of more immediate interest to investors is Trelegy Ellipta, GlaxoSmithKline’s new disposable inhaler medication developed as a maintenance treatment for asthma, which was approved by the FDA in September 2020. This approval gives Theravance a share of the revenue for a drug with a broad potential audience, as asthma affects more than 350 million people worldwide. Theravance owns royalties on Trelegy, with revenues ranging from 5.5% to 8.5% of total sales. Trelegy was initially approved in the US as the first single triple triple inhaler therapy to treat COPD. Like many biopharmacies, Theravance has high overheads and is the approved drug at the beginning of their lucrative lives. This keeps net earnings and income low, at least for the short term, and leads to a discounted price – TBPH has fallen by 32% over the past 52 weeks. Analyst Geoff Porges, who covers the stock for Leerink, remains strong on Theravance, mainly due to the combination of its strong pipeline and the approved treatments for lung diseases. Theravance’s respiratory medicine is the most important valuation driver in the short term … We are still predicting $ 2.4 billion in WW Triple sales at peak (2027E). In addition to TBPH’s commercial / partnership assets, the company is also developing an enhanced JAK inhibitor (JAKi), along with JNJ (OP) for inflammatory bowel disease (IBD), and a norepinephrine and serotonin reuptake inhibitor (NSRI) TD 9855 (ampreloxetine) for neurogenic orthostatic hypotension (nOH). “Each of these drugs uses new delivery of unique compounds against proven mechanisms of action and can provide better safety and / or treatment effects due to their wider therapeutic windows,” Porges noted. For this purpose, Porges rates TBPH as a better performance (ie buy) and gives it a price target of $ 35, which implies an impressive upward one-year of 104%. (To see Porges’ record, click here.) Overall, there are 5 reviews on the file, and it’s all for sale, which makes the consensus on strong buy unanimous. TBPH shares cost $ 16.95, and their average price target of $ 33.60 indicates a 97% rise from the level. (See TBPH stock analysis on TipRanks) NiSource, Inc. (NI) NiSource is a utility industry with subsidiaries in the natural gas and electricity sector. NiSource supplies power and gas to more than 4 million customers in Indiana, Kentucky, Maryland, Massachusetts, Ohio, Pennsylvania and Virginia. The majority of NiSource’s customers, about 88%, are in the gas sector; the company’s electrical operations only serve customers in Indiana. Revenue rose to $ 902 million in the third quarter, from $ 962 in the previous quarter and $ 931 in the previous quarter. Overall, however, revenue has met the company’s historical pattern: the second and third quarters are relatively low, while the top line increases with cold weather in the fourth quarter and in the first quarter. This is typical of utility companies in North America. Despite lower year-on-year earnings, NiSource felt confident in maintaining its dividend payout, keeping it at 21 cents per ordinary share until 2020. It gives a return of 84 cents and yields a return of 3 , 8%. The company not only had the confidence to pay income to shareholders, but also confident to invest in renewable energy sources. The company has an FY20 capital expenditure plan of more than $ 1.7 billion and is targeting $ 1.3 billion for FY21. These expenditures will fund ‘green’ energy projects. NI is currently trading at $ 21.67, a striking distance from the 52-week low. However, one analyst believes that the lower share price today gives investors an attractive entry point. Argus analyst Gary Hovis rated NI a buy with a price target of $ 32. This figure implies a 48% increase from current levels. (To view Hovis’ record, click here.) “NI shares look 18.1 times higher than our 2021 EPS estimate, below the average multiple of 21.6 for comparable electric and gas supplies,” Hovis noted. “NiSource could also become a buyout target, as larger utilities and private equity firms bought smaller utilities because of their stable earnings growth and above-average dividend yields.” Overall, Wall Street sees a clear path forward for NiSource – a fact evident from the unanimous consensus rating of the strong buy, based on three recent buy-side reviews. The stock is selling for $ 21.68, and the average price target of $ 28.75 indicates an increase of ~ 32% over a period of one year. (See NI stock analysis on TipRanks.) To find great ideas for struggling stocks trading at attractive valuations, visit TipRanks ‘best-selling stocks, a newly introduced tool that unites all the insights of TipRanks’ stocks. Disclaimer: The opinions expressed in this article are solely those of the proposed analysts. The content is for informational purposes only. It is very important to do your own analysis before investing.